Click here to close now.




















Welcome!

News Feed Item

SMC Accepts Rienso®▼ (Ferumoxytol), Offering Eligible Patients an Alternative Treatment Choice for Managing Iron Deficiency Anaemia in Chronic Kidney Disease

HIGH WYCOMBE, England, February 11, 2013 /PRNewswire/ --


  • Today, the SMC announced that Rienso has been accepted for restricted use within NHS Scotland for the treatment of iron deficiency anaemia (IDA) in non-haemodialysis dependent adult patients with chronic kidney disease (CKD) when oral iron preparations are ineffective or cannot be used
  • The clinical efficacy and safety of Rienso has been assessed in over 1,500 subjects from its clinical development programme, and supported by observational data in more than 8,600 patients and 33,000 doses administered in clinical practice1-3
  • Rienso offers a convenient and cost-competitive alternative for delivering a repletion course of IV iron, and requires fewer bolus injections over a shorter period of time when compared to most other IV iron preparations1,4-8
  • Takeda looks forward to making Rienso available to patients in Scotland as part of its ongoing commitment to improving management of IDA

Today, Takeda UK announces the Scottish Medicines Consortium's (SMC) acceptance of Rienso (ferumoxytol), a new intravenous (IV) iron therapy to treat iron deficiency anaemia (IDA) restricted to non-haemodialysis dependent adult patients with chronic kidney disease (CKD) when oral iron preparations are ineffective or cannot be used. All eligible patients in NHS Scotland will now be able to receive Rienso, offering a convenient and cost-effective alternative to current IV iron therapies.1,4-8

"Rienso will be a valuable addition to the currently available therapies for IDA as an effective and convenient method for delivering high dose iron; a significant consideration for non-dialysis patients who maintain an independent lifestyle. Its acceptance by the SMC will be of real benefit to the Scottish renal community." - Professor Alan Jardine, University of Glasgow.

Anaemia continues to place a significant burden on the daily lives of CKD patients, despite the availability of treatments to address the condition.9 Effective and efficient delivery of high doses of IV iron can lead to less disruption to the daily life of CKD patients, brought about by less time spent away from their home, family and work.8 Additionally, fewer patient visits can help improve the efficiency of service delivery leading to cost savings for the NHS.8

Marketing authorisation for Rienso was granted by the European Commission on 15 June 2012.1 Administered as a rapid IV injection, Rienso can be given to most adults as two x 510 mg doses administered 2-8 days apart, the benefits of which are rapid repletion of iron stores in anaemic CKD patients, with fewer bolus injections when compared to most other IV iron preparations.1,4-8 Rienso also offers the NHS a cost-competitive solution when compared to the alternative high bolus dose IV iron.7

Iron deficiency is a common cause of anaemia often seen in the later stages of CKD, and can have a profound impact on patients' lives, causing fatigue, shortness of breath and an increase in the risk of cardiovascular (CV) complications including congestive heart failure.9 Management of IDA is therefore an important aspect of care for patients with CKD and in Scotland alone, over 11,000 non-haemodialysis dependent CKD patients are estimated to suffer from anaemia.10

"Takeda are committed to improving the lives of patients worldwide, particularly in CKD, a profoundly debilitating condition for the patients who suffer from it. Acceptance of Rienso by the SMC marks an important milestone in providing physicians with a valuable alternative in the management of CKD patients with IDA in Scotland." - Yasuhiro Fukutomi, Managing Director of Takeda UK.

Rienso has been shown in clinical studies to significantly increase haemoglobin levels, with a similar overall treatment-related adverse event rate as compared to oral iron across the spectrum of CKD; based on data from over 1,500 subjects.1 Compared to the most widely prescribed IV iron preparation, the FIRST (Ferumoxytol Compared to Iron Sucrose Trial) study demonstrated that Rienso, delivered as two injections of 510 mg within 2-8 days, had a similar safety and comparable efficacy profile to 1 g of iron sucrose dosed as 100 mg or 200 mg over 5 to 10 injections within 2-2.5 weeks.11

Moreover, these data are supported by additional retrospective analyses conducted in the United States involving more than 8,600 patients and more than 33,300 administered doses of Rienso.2,3

NOTES FOR EDITORS

Recommendation from the SMC

ADVICE: following a full submission

Ferumoxytol (Rienso®) is accepted for restricted use within NHS Scotland.

Indication under review: Intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease.

SMC restriction: treatment of iron deficiency anaemia in non-haemodialysis dependent adult patients with chronic kidney disease when oral iron preparations are ineffective or cannot be used.

In two Phase III studies the mean increase from baseline in haemoglobin was significantly higher for ferumoxytol than oral iron in non-haemodialysis dependent patients with chronic kidney disease. A mixed treatment comparison demonstrated equivalent efficacy outcomes for ferumoxytol versus a range of intravenous iron preparations.

About Rienso® (ferumoxytol) 

Ferumoxytol is an IV iron therapy with an approved indication for the treatment of IDA in adult patients with CKD. When patients are iron deficient ferumoxytol can be administered as an initial 510 mg intravenous injection, followed by a second 510 mg intravenous injection 2-8 days later. For patients with Hb ≤10 g/dL, or 10-12 g/dL and > 50 kg in body weight; the recommended course of ferumoxytol is two injections of 510 mg intravenous iron. Ferumoxytol significantly increases Hb levels in CKD patients with IDA, both on dialysis and in patients not on dialysis compared with oral iron. Clinical trials have also highlighted that ferumoxytol is well tolerated.1

Ferumoxytol was developed by AMAG Pharmaceuticals, Inc (AMAG).1 It received marketing approval as Feraheme from the United States Food and Drug Administration on June 30, 2009 and was commercially launched by AMAG in the United States shortly thereafter. Ferumoxytol received marketing approval in Canada in December 2011, in the European Union in June 2012 and in Switzerland in August 2012, where it will be marketed by Takeda as Rienso®.

A Summary of Product Characteristics is available on the website http://www.medicines.org.uk.

About Takeda

Takeda UK Ltd. is based in High Wycombe, Buckinghamshire and is the UK subsidiary of Takeda Pharmaceuticals Company, responsible for sales and marketing of the company's medicines in the UK.

Located in Osaka, Japan, Takeda Pharmaceutical Company is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.

Further information about Takeda in the UK is available at http://www.takeda.co.uk.

References

  1. Rienso Summary of Product Characteristics (SmPC). Available online at: http://www.medicines.org.uk. Accessed January 2013.
  2. Schiller B, Bhat P, Sharma A, et al. Safety of Feraheme® (Ferumoxytol) in hemodialysis patients at 3 dialysis chains over a 1-year period. J Am Soc Nephrol 2011; 22: 477A-478A. Abstr FR-PO1573.
  3. Sharma A, Bhat P, Schiller B, et al. Efficacy of Feraheme® (Ferumoxytol) administration on target hemoglobin levels and other iron parameters across 3 dialysis chains. J Am Soc Nephrol 2011; 22: 485A. Abstr FR-PO1603.
  4. Venofer SmPC. Available online at: http://www.medicines.org.uk. Accessed January 2013.
  5. CosmoFer SmPC. Availabe online at: http://www.medicines.org.uk. Accessed January 2013.
  6. Monofer SmPC. Available online at: http://www.medicines.org.uk. Accessed January 2013.
  7. Monthly Index of Medical Specialities (MIMS). January 2013.
  8. Bhandari S. Beyond efficacy and safety - the need for convenient and cost-effective iron therapy in health care. NDT Plus 2011; 4(Suppl 1): i14-i19.
  9. O'Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectrum 2008; 21: 12-19.
  10. Scottish Intercollegiate Guidelines Network. Diagnosis and management of chronic kidney disease. 2008. Available online at: http://www.sign.ac.uk. Accessed January 2013.
  11. Macdougall IC, McLaughlin J, Fortin GS, Li Z, Strauss WE. The FIRST head-to-head comparison study (Ferumoxytol compared to Iron Sucrose Trial) of the safety and efficacy of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with chronic kidney disease. Presented November 2011 at ASN Kidney Week 2011.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
ElasticBox, the agile application delivery manager, announced freely available public boxes for the DevOps community. ElasticBox works with enterprises to help them deploy any application to any cloud. Public boxes are curated reference boxes that represent some of the most popular applications and tools for orchestrating deployments at scale. Boxes are an adaptive way to represent reusable infrastructure as components of code. Boxes contain scripts, variables, and metadata to automate proces...
Puppet Labs is pleased to share the findings from our 2015 State of DevOps Survey. We have deepened our understanding of how DevOps enables IT performance and organizational performance, based on responses from more than 20,000 technical professionals we’ve surveyed over the past four years. The 2015 State of DevOps Report reveals high-performing IT organizations deploy 30x more frequently with 200x shorter lead times. They have 60x fewer failures and recover 168x faster
To support developers and operations professionals in their push to implement DevOps principles for their infrastructure environments, ProfitBricks, a provider of cloud infrastructure, is adding support for DevOps tools Ansible and Chef. Ansible is a platform for configuring and managing data center infrastructure that combines multi-node software deployment, ad hoc task execution, and configuration management, and is used by DevOps professionals as they use its playbooks functionality to autom...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
Containers are not new, but renewed commitments to performance, flexibility, and agility have propelled them to the top of the agenda today. By working without the need for virtualization and its overhead, containers are seen as the perfect way to deploy apps and services across multiple clouds. Containers can handle anything from file types to operating systems and services, including microservices. What are microservices? Unlike what the name implies, microservices are not necessarily small,...
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Learn what is going on, contribute to the discussions, and e...
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!
It’s been proven time and time again that in tech, diversity drives greater innovation, better team productivity and greater profits and market share. So what can we do in our DevOps teams to embrace diversity and help transform the culture of development and operations into a true “DevOps” team? In her session at DevOps Summit, Stefana Muller, Director, Product Management – Continuous Delivery at CA Technologies, answered that question citing examples, showing how to create opportunities for ...
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
The 3rd International WebRTC Summit, to be held Nov. 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 15th International Cloud Expo, 6th International Big Data Expo, 3rd International DevOps Summit and 2nd Internet of @ThingsExpo. WebRTC (Web-based Real-Time Com...
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of ...